多西他赛腹腔灌注控制恶性腹水的临床疗效观察

Clinical efficacy of intraperitoneal chemotherapy with docetaxel in treatment of malignant ascites

目的探讨多西他赛腹腔灌注化疗控制恶性腹水的有效性和安全性。方法 2010年7月～2012年1月,给17例合并大量恶性腹水患者腹腔灌注40mg多西他赛D1,每28d为1周期,每完成1个周期评价疗效及安全性。结果17例患者中,3例CR,5例PR,总有效率47.1%;不良反应主要有骨髓抑制(88.2%),恶心、呕吐(100%),腹痛(70.6%),腹泻(52.9%)等,其中大部分为轻到中度。结论对一般情况较差的晚期肿瘤患者,多西他赛腹腔灌注控制恶性腹水疗效确切,耐受良好。

Objective To evaluate the clinical efficacy and safety of intraperitoneal chemotherapy with docetaxel in treatment of malignant ascites.Methods All 17 cases with massive ascites were received docetaxel 40mg ip,on day 1,four weeks as a cycle.Results In all of 17 patients,all over response rate was 47.1%,including 3 cases with complete remission（CR） and 5 with partial remission（PR）.The most common side effects were bone marrow suppression,nausea,vomiting,abdominal pain,diarrhea and so on,most of them were mild or moderate.Conclusion For generally poor patients,intraperitoneal chemotherapy with docetaxel in treatment of malignant ascites is effective and well tolerated.